NCT01614912View on ClinicalTrials.gov

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

SM-13496

40 or 80 mg once daily orally

Trial Locations (4)

Unknown

69 Sites, Tokyo, Etc

10 Sites, Kuala Lumpur, Etc

22 Sites, Seoul, Etc

14Sites, Taipei, Etc

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT01614912 - Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter